|
About UsVentripoint Diagnostics Ltd. (TSXV:VPT, OTCQB:VPTDF), headquartered in Toronto, Canada, is a medical device company engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease – a leading cause of death for both men and women worldwide.
The Company is developing a suite of applications for all major heart diseases and imaging modalities, including congenital heart disease, pulmonary hypertension and cardiotoxicity in oncology patients - a multi-billion dollar market potential. |
The Ventripoint Medical System
|
Ventripoint’s VMS+ 3.0 system connects to standard echo machines, the most widely used cardiac imaging technology globally. The system uses a proprietary Knowledge Based Reconstruction (KBR) technology to create 3D images of the heart and calculates volumes & ejection fraction with accuracy equivalent to MRI.
3D view of Right Ventricle showing End-Systolic and End-Diastolic
|
Our Technology |
The Company's Knowledge Based Reconstruction (KBR) algorithm allows for the creation of a 3D model of all chambers of the heart, right and left ventricles and right and left atria, using images generated from existing 2D and 4D imaging equipment. The Company’s technology platform is applicable to all heart diseases for adults and pediatrics.
The VMS system is based upon patented technology licensed on an exclusive basis from the University of Washington. |
